|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MRPL58 |
Gene summary for MRPL58 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MRPL58 | Gene ID | 3396 |
| Gene name | mitochondrial ribosomal protein L58 | |
| Gene Alias | DS-1 | |
| Cytomap | 17q25.1 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | Q14197 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3396 | MRPL58 | GSM4909285 | Human | Breast | IDC | 1.60e-33 | 5.53e-01 | 0.21 |
| 3396 | MRPL58 | GSM4909287 | Human | Breast | IDC | 1.48e-02 | 2.13e-01 | 0.2057 |
| 3396 | MRPL58 | GSM4909290 | Human | Breast | IDC | 1.09e-15 | 4.57e-01 | 0.2096 |
| 3396 | MRPL58 | GSM4909291 | Human | Breast | IDC | 4.45e-02 | 2.37e-01 | 0.1753 |
| 3396 | MRPL58 | GSM4909308 | Human | Breast | IDC | 1.42e-03 | 1.96e-01 | 0.158 |
| 3396 | MRPL58 | GSM4909317 | Human | Breast | IDC | 6.95e-04 | 2.15e-01 | 0.1355 |
| 3396 | MRPL58 | GSM4909319 | Human | Breast | IDC | 5.24e-05 | 7.02e-02 | 0.1563 |
| 3396 | MRPL58 | GSM4909321 | Human | Breast | IDC | 1.27e-02 | 2.29e-01 | 0.1559 |
| 3396 | MRPL58 | brca1 | Human | Breast | Precancer | 7.01e-03 | -8.24e-02 | -0.0338 |
| 3396 | MRPL58 | brca2 | Human | Breast | Precancer | 7.01e-03 | -8.24e-02 | -0.024 |
| 3396 | MRPL58 | brca3 | Human | Breast | Precancer | 7.01e-03 | -8.24e-02 | -0.0263 |
| 3396 | MRPL58 | P2 | Human | Breast | IDC | 4.05e-06 | 4.18e-01 | 0.21 |
| 3396 | MRPL58 | DCIS2 | Human | Breast | DCIS | 1.08e-35 | 1.85e-01 | 0.0085 |
| 3396 | MRPL58 | LZE2T | Human | Esophagus | ESCC | 1.45e-02 | 3.05e-01 | 0.082 |
| 3396 | MRPL58 | LZE4T | Human | Esophagus | ESCC | 8.03e-08 | 2.96e-01 | 0.0811 |
| 3396 | MRPL58 | LZE8T | Human | Esophagus | ESCC | 4.33e-03 | 1.10e-01 | 0.067 |
| 3396 | MRPL58 | LZE22T | Human | Esophagus | ESCC | 1.27e-08 | 5.28e-01 | 0.068 |
| 3396 | MRPL58 | LZE24T | Human | Esophagus | ESCC | 2.15e-14 | 3.58e-01 | 0.0596 |
| 3396 | MRPL58 | LZE21T | Human | Esophagus | ESCC | 5.81e-04 | 3.92e-01 | 0.0655 |
| 3396 | MRPL58 | HCC1 | Human | Liver | HCC | 2.65e-02 | 2.31e+00 | 0.5336 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00224119 | Breast | Precancer | cellular component disassembly | 44/1080 | 443/18723 | 3.17e-04 | 4.51e-03 | 44 |
| GO:00325432 | Breast | IDC | mitochondrial translation | 13/1434 | 76/18723 | 4.81e-03 | 3.67e-02 | 13 |
| GO:003254311 | Breast | DCIS | mitochondrial translation | 13/1390 | 76/18723 | 3.70e-03 | 2.99e-02 | 13 |
| GO:002241113 | Breast | DCIS | cellular component disassembly | 48/1390 | 443/18723 | 5.35e-03 | 3.92e-02 | 48 |
| GO:002241112 | Liver | HCC | cellular component disassembly | 282/7958 | 443/18723 | 1.02e-19 | 1.38e-17 | 282 |
| GO:01400531 | Liver | HCC | mitochondrial gene expression | 82/7958 | 108/18723 | 1.49e-12 | 7.20e-11 | 82 |
| GO:00325431 | Liver | HCC | mitochondrial translation | 62/7958 | 76/18723 | 2.95e-12 | 1.34e-10 | 62 |
| GO:003298411 | Liver | HCC | protein-containing complex disassembly | 138/7958 | 224/18723 | 5.59e-09 | 1.46e-07 | 138 |
| GO:00436242 | Liver | HCC | cellular protein complex disassembly | 71/7958 | 136/18723 | 1.39e-02 | 4.95e-02 | 71 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MRPL58 | SNV | Missense_Mutation | c.169N>G | p.Thr57Ala | p.T57A | Q14197 | protein_coding | tolerated(0.26) | benign(0.007) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MRPL58 | SNV | Missense_Mutation | novel | c.278N>G | p.Asn93Ser | p.N93S | Q14197 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MRPL58 | SNV | Missense_Mutation | novel | c.236N>C | p.Ile79Thr | p.I79T | Q14197 | protein_coding | deleterious(0) | possibly_damaging(0.697) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |
| MRPL58 | SNV | Missense_Mutation | rs375880126 | c.434G>A | p.Arg145Gln | p.R145Q | Q14197 | protein_coding | tolerated(0.13) | probably_damaging(0.949) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRPL58 | SNV | Missense_Mutation | novel | c.7N>A | p.Ala3Thr | p.A3T | Q14197 | protein_coding | tolerated_low_confidence(0.15) | benign(0.007) | TCGA-AJ-A3NE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MRPL58 | SNV | Missense_Mutation | rs747226298 | c.226C>T | p.Arg76Cys | p.R76C | Q14197 | protein_coding | deleterious(0.03) | benign(0.426) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| MRPL58 | SNV | Missense_Mutation | c.335C>T | p.Ala112Val | p.A112V | Q14197 | protein_coding | deleterious(0) | benign(0.284) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MRPL58 | SNV | Missense_Mutation | rs751797695 | c.535N>G | p.Arg179Gly | p.R179G | Q14197 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BK-A13B-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| MRPL58 | SNV | Missense_Mutation | novel | c.523C>A | p.Leu175Ile | p.L175I | Q14197 | protein_coding | deleterious(0.05) | possibly_damaging(0.715) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRPL58 | SNV | Missense_Mutation | rs764514778 | c.553C>T | p.Arg185Trp | p.R185W | Q14197 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |